Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 17, 2026Frontiers in MicrobiologyOpen Access

MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

View Full Paper
Ask AI
Bookmark
Share

Authors

BLBastien LaperrousazJRJulie ReygnerMSMargaux De Seilhac

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Laperrousaz et al. (2026) studied this question.

synapsesocial.com/papers/6aabb6635f706d05830e4be6https://doi.org/10.3389/fmicb.2026.1920614
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 2868: MaaT013 pooled fecal microbiotherapy improves gastrointestinal physiology and controls inflammation which delays GvHD in a proof-of-concept humanized mouse study2026
  2. 2Multi-omics analysis of a fecal microbiota transplantation trial identifies novel aspects of acute graft-versus-host disease pathogenesis2024 · 14 citations
  3. 3The role of microbial metabolites in fecal microbiota transplantation in patients with acute gvhd of the gut2025
  4. 4Data from Multi-omics Analysis of a Fecal Microbiota Transplantation Trial Identifies Novel Aspects of Acute GVHD Pathogenesis2024
  5. 5Enteral supplementation with a TGF-β-enriched polymeric diet mitigates gastrointestinal acute gvhd2025